AbbVie: Cystic Fibrosis trials

The registry lists 17 Cystic Fibrosis studies with AbbVie as lead sponsor. 0 are open to participants now and 12 have results posted.

Phase 1 1Phase 2 2Phase 3 6Phase 4 6No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With CreonCompletedNCT05069597Phase 4Results posted
• Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic FibrosisTerminatedNCT04853368Phase 2Results posted
• A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222CompletedNCT03969888Phase 2Results posted
• A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic FibrosisCompletedNCT03924947Phase 4Results posted
• Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic InsufficiencyCompletedNCT01327703Phase 4Results posted
• PR-018: An Open-Label, Safety Extension of Study PR-011CompletedNCT01131507Phase 4Results posted
• A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of AgeCompletedNCT01100606Phase 4Results posted
• Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic InsufficiencyCompletedNCT00981214Phase 3Results posted
• Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)CompletedNCT00880100Phase 3Results posted
• Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)CompletedNCT00513682Phase 3Results posted
• Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)CompletedNCT00408317Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic InsufficiencyCompletedNCT00297167Phase 3Results posted
• A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic FibrosisCompletedNCT05530278Phase 1
• Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pancreatic Insufficiency Not Due To Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic CancerWithdrawnNCT04315311Phase 4
• Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement TherapyCompletedNCT01858519
• Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)TerminatedNCT01652157
• Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.CompletedNCT01641393Phase 3